Business Wire

CSG Wins Business Impact Honor at TM Forum Catalyst Awards

18.4.2023 16:30:00 EEST | Business Wire | Press release

Share

CSG® (NASDAQ: CSGS) today announced that it was selected as a winner in the 2023 TM Forum Catalyst Awards. The awards celebrate the most successful innovation of the telecoms industry, proof-of-concepts for industry standards, and impact on sustainability goals. Conducted in participation with Microsoft, Nokia, and Vodafone, the CSG Channels & Markets Phase II project was recognized as an Outstanding Catalyst for Business Impact.

“Dynamic marketplaces present many opportunities for CSPs in B2B and B2B2X sectors, where cross-functional collaboration has become the new currency for success,” said Greg Tilton, VP of catalog, quote & order, CSG. “Collaboration is critical, which is why CSG joined forces with Microsoft, Nokia and Vodaphone to enable CSPs to capture new market segments beyond connectivity and thrive. We're honored to receive this recognition, and I extend a big thank you to our partners for the success we’ve achieved with the TM Forum Channel & Markets Phase II Catalyst."

The Catalyst project proves the capabilities of TM Forum Open APIs to support exposure across all channels for providers in and outside a B2B2X ecosystem. It simplifies the creation of dynamic B2B2X marketplaces so that CSPs can seamlessly bundle and market products that tap the powerful capabilities of third-party suppliers. Thanks to its zero-code design, it also enables a faster time to market, providing a competitive advantage in a dynamic field. This second phase of the Catalyst introduces new configurable components to TM Forum Open APIs with four main objectives:

  • Remove catalog barriers to unlock powerful new B2B2X business models.
  • Introduce configurable domain-specific service specifications to support connectivity and non-connectivity services that CSPs want to add.
  • Develop an API-powered model for assisted and self-service channels to co-exist.
  • Provide zero-code design-time and prove commercially viable run-time experience.

“CSPs today need partners to elevate their offerings, drive growth, and prepare for the ever more competitive future,” said Keith Sutton, CTO media and communications service line, industry solutions transformation, Microsoft. “Our catalyst project with CSG, Nokia, and Vodafone provides an end-to-end solution that not only lowers costs and shortens time to market but also allows CSPs to be more agile and future-forward in their customer interactions. It is a testament to our collective commitment to help telecom players build new digital marketplaces to thrive and succeed today while driving their future growth.”

TM Forum announced the Catalyst Award winners during Digital Transformation World Asia. Honoring the innovation and impact of its members in the industry, TM Forum acknowledged a total of four Catalyst proof-of-concept projects as ‘Outstanding Catalysts’ for their significant contributions to the acceleration of digital transformation across the industry.

About CSG

CSG empowers companies to build unforgettable experiences, making it easier for people and businesses to connect with, use and pay for the services they value most. Our customer experience, billing and payments solutions help companies of any size make money and make a difference. With our SaaS solutions, company leaders can take control of their future and tap into guidance along the way from our fiercely committed and forward-thinking CSGers around the world.

Want to learn more about how to be a change-maker and industry shaper like our 1,000-plus clients? Visit csgi.com to learn more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kristine Østergaard
Public Relations
+44 (0)79 2047 7204
kristine.ostergaard@csgi.com

John Rea
Investor Relations
+1 (210) 687-4409
john.rea@csgi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye